 |
 |
 |
|
Quantification of the Effect of Adherence to Clinical Outcomes in Telaprevir-based Regimens
|
|
|
Reported by Jules Levin
HEP DART 2011, Koloa, Hawaii, USA, December 4-8, 2011
BS Adiwijaya1, TL Kieffer1, N Adda1, S George1, V Garg1
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States








|
|
|
 |
 |
|
|